Pleconaril (Synonyms: VP 63843; Win 63843)

Name: Pleconaril
Brand: MedChemExpress
SKU: HY-19952
Rating: 4.5 (1 reviews)

Cat. No.: HY-19952 Purity: 99.48%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Pleconaril is a picornavirus capsid binding inhibitor that prevents attachment and/or virus uncoating. Pleconaril has potential for use in rhinoviruses and enteroviruses research.

For research use only. We do not sell to patients.

Pleconaril Chemical Structure

CAS No. : 153168-05-9

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 106	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 106	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 96	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 145	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 275	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 413	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 600	In-stock	Estimated Time of Arrival: December 31
200 mg	USD 870	In-stock	Estimated Time of Arrival: December 31
500 mg		Get quote
1 g		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Pleconaril:

Pleconaril-d₄ Get quote
Pleconaril (Standard) Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Pleconaril is a picornavirus capsid binding inhibitor that prevents attachment and/or virus uncoating. Pleconaril has potential for use in rhinoviruses and enteroviruses research^[1]^[2].

Cellular Effect

Cell Line	Type	Value	Description	References
H1-HeLa	CC₅₀	19.7 μM Compound: Pleconaril	Cytotoxicity against human H1HeLa cells assessed as reduction in cell viability after 3 days by MTT assay Cytotoxicity against human H1HeLa cells assessed as reduction in cell viability after 3 days by MTT assay	[PMID: 30034598]
H1-HeLa	CC₅₀	19.7 μM Compound: 1	Cytotoxicity against human H1HeLa cells assessed as decrease in cell viability after 3 days by MTT assay Cytotoxicity against human H1HeLa cells assessed as decrease in cell viability after 3 days by MTT assay	[PMID: 28581749]
H1-HeLa	CC₅₀	20.8 μM Compound: Pleconaril	Cytotoxicity against human H1-HeLa cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human H1-HeLa cells assessed as reduction in cell viability by MTT assay	[PMID: 35292344]
H1-HeLa	CC₅₀	53.5 μM Compound: Pleconaril	Cytotoxicity in human H1HeLa cells assessed as reduction in cell viability incubated for 3 days by MTT assay Cytotoxicity in human H1HeLa cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 28587824]
HeLa	EC₅₀	> 42.8 μM Compound: Pleconaril	Antiviral activity against human coxsackievirus B3 infected in human HeLa cells assessed as reduction in virus-induced cytopathicity incubated for 3 days by MTT assay Antiviral activity against human coxsackievirus B3 infected in human HeLa cells assessed as reduction in virus-induced cytopathicity incubated for 3 days by MTT assay	[PMID: 28587824]
HeLa	IC₅₀	≤ 0.18 μM Compound: 55; WIN63843	Cytotoxicity against human HeLa cells after 3 days by MTT assay Cytotoxicity against human HeLa cells after 3 days by MTT assay	[PMID: 31226653]
HeLa	EC₅₀	0.13 μM Compound: Pleconaril	Antiviral activity against human coxsackievirus B1 infected in human HeLa cells assessed as reduction in virus-induced cytopathicity incubated for 3 days by MTT assay Antiviral activity against human coxsackievirus B1 infected in human HeLa cells assessed as reduction in virus-induced cytopathicity incubated for 3 days by MTT assay	[PMID: 28587824]
HeLa	EC₅₀	0.51 μM Compound: Pleconaril	Antiviral activity against human poliovirus 3 infected in human HeLa cells assessed as reduction in virus-induced cytopathicity incubated for 3 days by MTT assay Antiviral activity against human poliovirus 3 infected in human HeLa cells assessed as reduction in virus-induced cytopathicity incubated for 3 days by MTT assay	[PMID: 28587824]
HeLa	EC₅₀	1.4 μM Compound: 1	Antiviral activity against Human poliovirus 3 infected in human HeLa cells assessed as protection against virus induced cytopathic effect after 2 days by MTT assay Antiviral activity against Human poliovirus 3 infected in human HeLa cells assessed as protection against virus induced cytopathic effect after 2 days by MTT assay	[PMID: 28581749]
HeLa	CC₅₀	12.6 μg/mL Compound: pleconaril	Cytotoxicity against human HeLa cells after 72 hrs Cytotoxicity against human HeLa cells after 72 hrs	[PMID: 18247552]
HeLa	CC₅₀	131 μM Compound: Pleconaril	Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 29039946]
HeLa	EC₅₀	177 nM Compound: Pleconaril	Antienteroviral activity against Human rhinovirus 14 infected in human HeLa cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay Antienteroviral activity against Human rhinovirus 14 infected in human HeLa cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay	[PMID: 24900715]
HeLa	EC₅₀	224.1 ng/mL Compound: 1	Antirhinoviral activity against Human rhinovirus B infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antirhinoviral activity against Human rhinovirus B infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24900468]
HeLa	EC₅₀	23.2 ng/mL Compound: 1	Antirhinoviral activity against minor receptor-resistant Human rhinovirus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antirhinoviral activity against minor receptor-resistant Human rhinovirus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24900468]
HeLa	CC₅₀	25.9 μM Compound: 1	Cytotoxicity aganist human HeLa cells assessed as decrease in cell viability after 2 days by MTT assay Cytotoxicity aganist human HeLa cells assessed as decrease in cell viability after 2 days by MTT assay	[PMID: 28581749]
HeLa	CC₅₀	26.25 μM Compound: Pleconaril	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs measured by crystal violet based micro plate reader method Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs measured by crystal violet based micro plate reader method	[PMID: 31881489]
HeLa	EC₅₀	33.8 ng/mL Compound: 1	Antirhinoviral activity against antiviral-resistant Human rhinovirus B infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antirhinoviral activity against antiviral-resistant Human rhinovirus B infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24900468]
HeLa	EC₅₀	37.4 ng/mL Compound: 1	Antirhinoviral activity against Human rhinovirus A infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antirhinoviral activity against Human rhinovirus A infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24900468]
HeLa	EC₅₀	387.6 ng/mL Compound: 1	Antirhinoviral activity against antiviral-resistant Human rhinovirus A infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antirhinoviral activity against antiviral-resistant Human rhinovirus A infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24900468]
HeLa	CC₅₀	42.8 μM Compound: Pleconaril	Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 3 days by MTT assay Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 28587824]
HeLa	EC₅₀	49.2 ng/mL Compound: 1	Antirhinoviral activity against major receptor-resistant Human rhinovirus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antirhinoviral activity against major receptor-resistant Human rhinovirus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24900468]
RD	CC₅₀	> 200 μM Compound: 1	Cytotoxicity against human RD cells assessed as inhibition of cell viability by measuring ATP level incubated for 72 hrs by cell titer-glo luminescent cell viability assay Cytotoxicity against human RD cells assessed as inhibition of cell viability by measuring ATP level incubated for 72 hrs by cell titer-glo luminescent cell viability assay	[PMID: 36254462]
RD	EC₅₀	13400 nM Compound: Pleconaril	Antienteroviral activity against Enterovirus 71 infected in human RD cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay Antienteroviral activity against Enterovirus 71 infected in human RD cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay	[PMID: 24900715]
Vero	EC₅₀	0.002 μM Compound: Pleconaril	Antiviral activity against Coxsackievirus B3 infected in Vero cells assessed as reduction in virus-induced cytopathic effect incubated for 48 hrs by Reed-Muench method Antiviral activity against Coxsackievirus B3 infected in Vero cells assessed as reduction in virus-induced cytopathic effect incubated for 48 hrs by Reed-Muench method	[PMID: 32378892]
Vero	EC₅₀	0.005 μM Compound: Pleconaril	Antiviral activity against Coxsackievirus B5 infected in African green monkey Vero 76 cells after 3 days by plaque reduction assay Antiviral activity against Coxsackievirus B5 infected in African green monkey Vero 76 cells after 3 days by plaque reduction assay	[PMID: 25913116]
Vero	EC₅₀	1084 nM Compound: Pleconaril	Antienteroviral activity against poliovirus 2 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay Antienteroviral activity against poliovirus 2 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay	[PMID: 24900715]
Vero	EC₅₀	13000 nM Compound: Pleconaril	Antienteroviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay Antienteroviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay	[PMID: 24900715]
Vero	EC₅₀	2.2 μM Compound: Pleconaril	Antiviral activity against Poliovirus Sb-1 infected in African green monkey Vero 76 cells after 2 days by plaque reduction assay Antiviral activity against Poliovirus Sb-1 infected in African green monkey Vero 76 cells after 2 days by plaque reduction assay	[PMID: 25913116]
Vero	EC₅₀	24200 nM Compound: Pleconaril	Antienteroviral activity against poliovirus 1 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay Antienteroviral activity against poliovirus 1 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay	[PMID: 24900715]
Vero	EC₅₀	33 nM Compound: Pleconaril	Antienteroviral activity against Coxsackievirus A9 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay Antienteroviral activity against Coxsackievirus A9 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay	[PMID: 24900715]
Vero	EC₅₀	84 nM Compound: Pleconaril	Antienteroviral activity against poliovirus 3 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay Antienteroviral activity against poliovirus 3 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay	[PMID: 24900715]
Vero 76	CC₅₀	> 100 μM Compound: Pleconaril	Cytotoxicity against African green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against African green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay	[PMID: 29339251]
Vero 76	EC₅₀	0.008 μM Compound: Pleconaril	Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay	[PMID: 26443549]
Vero 76	EC₅₀	2 μM Compound: Pleconaril	Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay	[PMID: 26443549]
Vero 76	CC₅₀	70 μM Compound: Pleconaril	Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method	[PMID: 26443549]
Vero 76	CC₅₀	80 μM Compound: Pleconaril	Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by MTT method Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by MTT method	[PMID: 25913116]
Vero 76	CC₅₀	83 μM Compound: Pleconaril	Cytotoxicity against African green monkey Vero 76 cells assessed as decrease in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against African green monkey Vero 76 cells assessed as decrease in cell viability after 48 to 96 hrs by MTT assay	[PMID: 29028528]

In Vitro

Pleconaril (0.4-50 µM, 2 days) produces substantial cytotoxicity at 50 μM concentrations in RD cells^[2].
Pleconaril (0.001-4 µg/mL, 24 h) increases the cell viability of RD cells infected with EV71^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Pleconaril (0.375-80 mg/kg, i.p., daily, 5 days) increases the number of viable mice infected with EV71^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

381.35

Formula

C₁₈H₁₈F₃N₃O₃

CAS No.

153168-05-9

Appearance

Solid

Color

White to off-white

SMILES

FC(C1=NC(C2=CC(C)=C(OCCCC3=CC(C)=NO3)C(C)=C2)=NO1)(F)F

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (262.23 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.6223 mL	13.1113 mL	26.2226 mL
5 mM	0.5245 mL	2.6223 mL	5.2445 mL
10 mM	0.2622 mL	1.3111 mL	2.6223 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.56 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.56 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.48%

Select Batch:

Data Sheet (270 KB) SDS (479 KB)

COA (245 KB) LCMS (95 KB)

Handling Instructions (2659 KB)

References

[1]. Benschop KS, et al. Genetic and antigenic structural characterization for resistance of echovirus 11 to pleconaril in an immunocompromised patient. J Gen Virol. 2015 Mar;96(Pt 3):571-9. [Content Brief]

[2]. Lee JS, et al. Antiviral Activity of Itraconazole against Echovirus 30 Infection In Vitro. Osong Public Health Res Perspect. 2017 Oct;8(5):318-324. [Content Brief]

[3]. Zhang G, et al. In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection. Arch Virol. 2012 Apr;157(4):669-79. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.6223 mL	13.1113 mL	26.2226 mL	65.5566 mL
	5 mM	0.5245 mL	2.6223 mL	5.2445 mL	13.1113 mL
	10 mM	0.2622 mL	1.3111 mL	2.6223 mL	6.5557 mL
	15 mM	0.1748 mL	0.8741 mL	1.7482 mL	4.3704 mL
	20 mM	0.1311 mL	0.6556 mL	1.3111 mL	3.2778 mL
	25 mM	0.1049 mL	0.5245 mL	1.0489 mL	2.6223 mL
	30 mM	0.0874 mL	0.4370 mL	0.8741 mL	2.1852 mL
	40 mM	0.0656 mL	0.3278 mL	0.6556 mL	1.6389 mL
	50 mM	0.0524 mL	0.2622 mL	0.5245 mL	1.3111 mL
	60 mM	0.0437 mL	0.2185 mL	0.4370 mL	1.0926 mL
	80 mM	0.0328 mL	0.1639 mL	0.3278 mL	0.8195 mL
	100 mM	0.0262 mL	0.1311 mL	0.2622 mL	0.6556 mL

Pleconaril Related Classifications

Infection

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Pleconaril (Synonyms: VP 63843; Win 63843)

Customer Review

Other Forms of Pleconaril:

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Pleconaril Related Classifications

Keywords:

Your Recently Viewed Products:

Name
Email *

	Sorry, but the email address you supplied was invalid.

Pleconaril (Synonyms: VP 63843; Win 63843)

Customer Review

Other Forms of Pleconaril:

Pleconaril Related Antibodies

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Pleconaril Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Pleconaril Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report